Studies of hematopoietic stem cell (HSC)-derived dendritic cells (DCs) are often limited by the rarity of HSC. To facilitate the study of DCs, we have generated a novel cell line (CR1) by retroviral Notch IC gene transfer into Sca1 þ ckit þ lin À HSC. CR1 cells proliferated in vitro in the presence of recombinant interleukin-3. They maintained an immature progenitor cell phenotype and an intact karyotype. In the presence of granulocyte-macrophage colony-stimulating factor or Flt3L, CR1 cells differentiated into myeloid and plasmacytoid DCs, respectively. Functionally, CR1 cells were comparable to primary bone-marrow-derived DCs with respect to Toll-likereceptor-mediated maturation, cytokine release and capacity to induce effective antitumor immunity. CR1 cells thus provide an elegant new cellular tool to study DC development, function and preclinical DC-based immunotherapies.
Introduction
Dendritic cells (DCs) play a fundamental role in modulating innate and adaptive immune responses. Thus, they have evoked considerable interest as potential tools for the development of cell therapies to induce antitumor immune responses. 1 In humans, large numbers of DCs can be generated from hematopoietic stem cells (HSC) or peripheral blood monocytes. In vitro-generated DCs are typically loaded with tumorassociated antigens and administered to patients. Despite recently encouraging clinical trials, several issues, potentially limiting the clinical success of DC-based therapies, are still unresolved. 2 We reasoned that the availability of a standardized cell line as a source for potentially unlimited numbers of DCs may be of benefit to further study preclinical aspects of DC-based therapies. The generation of immortalized multipotent hematopoietic progenitor cell lines has become possible by the retroviral gene transfer technologies. Defined transgenes, such as a dominant-negative version of the retinoic acid receptor 3 Notch1, 4 HoxB4 5 and b-catenin, 6 have been shown to expand HSC without inducing differentiation.
The Notch family of transmembrane receptors has been shown to play a critical role in regulating cell fate decisions in numerous developmental systems. In mammals, four Notch receptors (Notch1-4) and six ligands (Jagged-1 and -2, Delta-1, 2, -3, 4) have been identified. 7 Notch receptors induce proteolytic cleavage and nuclear translocation of the intracellular domain of Notch (Notch IC ). Notch IC has previously been shown to expand multipotent hematopoietic progenitor cells, 4 but their capacity to give rise to DCs has not yet been studied. Here, we report the generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential based on Notch IC gene transfer into HSC.
Results

Generation of CR-1 cells
First, we were interested to analyze the proliferation capacity of Notch IC -transduced HSC in the presence of various hematopoietic cytokines. We purified Sca1 þ ckit þ lin À HSC from C57BL/6 mice and transduced them with VSV-G pseudotyped retroviruses encoding either Notch IC -GFP (green fluorescent protein) or GFP. The transduction efficiency was 61% for GFPtransduced cells and 41% for Notch IC -GFP-transduced cells. Bulk cultures of retrovirus-transduced hematopoietic progenitor cells were grown in the presence of various cytokine combinations. Notch IC -transduced cells proliferated in the presence of interleukin-3 (IL-3), IL-3 þ SCF and IL-3 þ SCF þ IL-6 þ Flt3L, whereas various cytokines in the absence of IL-3 did not induce sustained growth. In contrast, GFP-transduced cells divided for 2 weeks before undergoing apoptosis. Figure 1a shows the result of an experiment determining the viability of Notch IC -and GFPtransduced cells 4 weeks after retroviral transduction. Compared to GFP-control-transduced cells, Notch IC -transduced cells grown in the presence of IL-3 revealed a significantly higher viability. The cells were maintained in the presence of recombinant IL-3, and named CR1.
Next, we characterized CR1 cells with respect to cell surface phenotype, cytogenetic stability and functional properties. CR1 cells expressed GFP and the pan-hematopoietic marker CD45. Further analysis of cell surface markers confirmed a phenotype consistent with early hematopoietic progenitor cells: CR1 cells did not express lineage markers (B220, CD3, CD11b, CD11c, GR1 and TER119) and stained positive for c-kit and Sca1 (Figure 1b) . Furthermore, the majority of cells expressed Thy1, and only a small subfraction expressed IL-7Ra or Fc-g, markers for committed lymphoid and myeloid progenitors, respectively (not shown). The cells were maintained for at least 6 months without change in morphology and immunophenotype.
As integration of retroviral proviruses and long-term in vitro culture may affect the cytogenetic stability of cell lines, we performed spectral karyotyping on CR-1 cells. As shown in Supplementary Figure 1 , a normal mouse karyotype was established, confirming that no major cytogenetic aberrations have occurred within 6 months of in vitro culture.
To assess the pluripotency and 'stemness' of CR1 cells, we performed transplantation experiments in congenic CD45.1 þ mice. This experimental system allows a simple and reliable determination of the relative contribution of endogenous and CR-1-derived hematopoiesis. To determine the in vivo differentiation potential of CR1 cells, recipient mice were conditioned with a sublethal dose of irradiation (4.5 Gy) and then injected with 1 Â 10 6 CR1 cells. Four weeks later, mice were killed and the contribution of CR1-derived hematopoiesis was assessed in single cell suspensions from bone marrow, spleen and thymus by fluorescence-activated cell sorting (FACS TER119 cells were seen in these mice, a finding consistent with earlier reports. [8] [9] [10] To further delineate the 'stemness' of CR1 cells, we also performed transplantation experiments in mice conditioned with a lethal dose of irradiation (9 Gy). In these experiments, all animals died at days 10-14 after irradiation, indicating that CR1 cells do not represent authentic HSC. Presumably, the lack of hematopoietic rescue is due to deficient differentiation into erythroid cells.
In some experiments, we followed sublethally irradiated mice injected with CR1 cells clinically to detect a leukemogenic potential. Within 5 months of observation period, none of the mice developed any signs or symptoms suggestive of malignancy.
In vitro dendritic cell differentiation potential Our original goal was to amplify hematopoietic progenitor cells for further use as a cellular source to generate DCs. In a subsequent series of experiments, we therefore characterized the potential of CR1 cells to differentiate into DC. CR-1 cells were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or Flt3L, two cytokines directing differentiation of 'myeloid' and 'lymphoid' DCs, respectively. Eight days later, the immunophenotype of the cells was determined by FACS. As shown in Figure 3a , CR1 cells cultured in the presence of GM-CSF differentiated into myeloid DCs characterized by expression of CD11c, CD40, CD80, CD86 and MHC class II. A similar immunophenotype was observed in cells cultured in the presence of Flt3L. In addition, the majority of Flt3L-induced cells also expressed B220, a hallmark of 'plasmacytoid' DCs ( Figure 3b ). Figure 3c shows the morphologic appearance of in vitro-generated DCs in comparison to non-differentiated CR1 cells. Taken together, these experiments confirmed that CR1 cells show in vitro differentiation potential into myeloid and plasmacytoid DC.
To further characterize CR-1-derived DCs, we assessed their functional properties. In a physiological setting, DCs undergo maturation upon stimulation with certain inflammatory cytokines or Toll-like-receptor (TLR) signalling. To further analyze CR-1-derived DCs, we also performed chemotaxis and phagocytosis experiments. Both myeloid and plasmacytoid DCs derived from CR-1 cells migrated toward an MIP3b gradient, whereas CR-1 cells did not respond to MIP3b ( Figure 5a ). As expected, both differentiated DC types were able to ingest Escherichia coli bacteria and thus revealed the capacity of phagocytosis (Figure 5b ). Myeloid and plasmacytoid DCs reveal differential expression of TLRs, and only plasmacytoid DCs respond to TLR9-mediated signals by expression of interferon (IFN)-a. We analyzed expression of TLR4 and TLR9 on CR-1-derived DCs and documented that expression of TLR4 was higher on myeloid DCs, whereas expression of TLR9 was higher on plasmacytoid DCs ( Figure 5c ). As expected, plasmacytoid DCs expressed IFN-a in response to CpG stimulation, as assessed by reverse transcriptase-PCR (RT-PCR) (Figure 5d ).
Antitumor effects
Finally, we made use of the novel CR1 cell line to assess DCbased immunotherapy for leukemia. We chose to focus on the well-established murine AML model C1498. 11 It has previously been shown that C1498 lysate-pulsed DCs induce protective leukemia-specific T-cell responses. 12 We isolated primary DCs and CR1-derived DCs, loaded the cells with C1498 lysates and injected 10 6 DCs subcutaneously. One week later, the mice were challenged with a lethal dose of C1498 leukemia cells. As shown in Figure 6 , CR-1-derived DCs induced a potent and long-lasting antileukemia immunity, comparable to the benchmark immunity elicited by primary DCs. We conclude that DCs generated from a defined cell line are as effective as primary DCs in the induction of antitumor immunity.
Discussion
We have shown that Notch IC gene transfer into HSC gives rise to hematopoietic progenitor cells (CR1) that can be efficiently differentiated into both myeloid and plasmacytoid DCs. Using CR1 cells, we also provide proof of principle that in vitrogenerated DCs can be used efficiently to induced antileukemia immunity.
Retroviral Notch IC gene transfer has previously been shown to generate multipotent HSC without compromising their differentiation potential. 4 Here, we confirm and extend these observations by showing that Notch IC -transduced HSC continuously expand in the presence of IL-3 maintaining an immature developmental stage and preserve their cytogenetic integrity.
The role of Notch1 signalling in myeloid development remains controversial. Some authors have shown that expression of Notch IC favors myeloid development, 12,13 whereas others reported that Notch IC favors lymphoid over myeloid development and inhibits granulocyte differentiation. 14, 15 With respect to DC differentiation, the function of Notch1 is equally unclear.
Using in vitro differentiation systems of Notch-1-null ES and HPC, Cheng et al. 16 have found that Notch-1 is necessary but not sufficient for DC differentiation. In contrast, Radtke et al. 
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reported that peripheral DCs, Langerhans cells and thymic DCs are not affected by Notch1 deficiency, suggesting that DC development is totally independent of Notch1. The resolution of these at first sight contradictory findings will require additional studies to establish whether and under which circumstances Notch1 plays permissive 18 or instructive roles 19 in the determination of myeloid cell fate or maturation. Our data clearly show that overexpression of Notch IC in progenitor cells does not inhibit their capacity to differentiate into myeloid and lymphoid DCs.
To our knowledge, no other hematopoietic precursor cell line shows similar convincing DC differentiation properties.
Schroeder et al. 20 and our own data 21 have shown that FDCP-mix cells could be differentiated into DCs in the presence of GM-CSF. In direct comparative studies however, the DC differentiation capacity of CR1 cells appears to be superior, as CR1-derived DCs resemble bone marrow-derived DCs very closely in phenotype, morphology and function. It will be interesting to assess comparatively DCs obtained from expanded progenitor cells carrying other transgenes such as HoxB4 or b-catenin.
We have also shown that CR1-derived DCs induce antitumor immunity in a murine leukemia model. Thus, it is possible to use immortalized hematopoietic progenitor cells as a source for DCs to induce antitumor immunity. In contrast to primary DCs, this system will allow a more standardized and quality-controlled approach to test various strategies of enhanced DC function. In particular, testing of further genetic modifications enhancing DC function will be greatly facilitated. 22 Genetically engineered hematopoietic progenitor cell lines may also be used in a wide variety of other cell therapy applications and for developmental studies. Preliminary evidence suggests that CR1 cells can also be differentiated into functional NK cells, thus obviating the intrinsic difficulty to generate large numbers of murine NK cells for use in preclinical cell therapy models (C Klein, unpublished). In addition to preclinical therapeutic studies, CR1 cells provide a standardized, easily available source to generate myeloid and plasmacytoid DCs for studies aiming at the elucidation of molecular control mechanisms of DC differentiation. Thus, CR1 cells should be of significant interest for both basic science studies and applied cellular therapeutic technologies.
The generation of hematopoietic progenitor cell lines requires gene transfer technologies that are inherently associated with a risk of insertional mutagenesis. In addition, transplantation of -expressing HSC has resulted in the onset of T-cell malignancies. 8, 23, 24 So far, we have not observed any toxic effects in animals treated with CR1-derived DCs, suggesting that differentiated DCs, even when expressing an oncogene, are less tumorigenic compared to non-differentiated progenitors. Most likely, the short lifespan of DCs upon injection is at least in part accountable for this effect.
At this stage, our studies are limited to murine hematopoietic progenitor cells. Before these concepts can be translated into clinical applications, several technical hurdles need to be addressed. Despite recent breakthroughs in amplifying human hematopoietic progenitor cells, 25 it still remains a difficult challenge to create multipotent human cell lines. Furthermore, as indicated above, feasibility studies need to be complemented by studies assessing potential risks. In this respect, the development of novel vectors with controlled transgene expression and optimized risk profiles may help to advance this rapidly expanding field of innovative cell and gene therapy.
Materials and methods
Cells and cell culture
CR1 cells were always maintained in the presence of 5 ng/ml rmIL-3 (Peprotech, Rocky Hill, NJ, USA) in IMDM medium supplemented with 10% FCS, 2 mM L-glutamine and 1% penicillin-streptomycin (all from Gibco, Karlsruhe, Germany). For differentiation of CR1 cells into DCs, 3 Â 10 6 cells were seeded per well in 3 ml of IMDM complete medium in a six-well plate. As a differentiation factor, either rmGM-CSF (5 ng/ml) or rhFlt3L (50 ng/ml) was added to promote myeloid and plasmocytoid DC differentiation, respectively. Cell culture medium with fresh cytokines was replaced after every 48 h and cells were cultured for either 8 or 12 days.
To generate bone marrow-derived DCs, bone marrow cells were depleted of Gr1
þ and B220 þ cells using magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Lineage-depleted progenitor cells were cultured in IMDM, 10% FCS, 2 mM L-glutamine, 1% penicillinstreptomycin, 1 mM non-essential amino acids and 5 Â 10 À5 M 2-mercaptoethanol for 7 days in the presence of recombinant murine GM-CSF and IL-4 (Sigma, Munich, Germany). The myeloid leukemia cell line C1498 was obtained from American Type Culture Collection (Rockville, MD, USA) and grown in AIM V, a serum-free medium (Gibco, Karlsruhe, Germany). Dendritic cells were incubated with freeze-thawed tumor lysates at a ratio of three tumor cell equivalents to one DC in RPMI complete. After 18 h of incubation, DCs were harvested, irradiated with 2500 cGy, washed and used for vaccination. Toll-like-receptor simulation was performed in the presence of 10 mM CpG-DNA (TibMolBiol, Berlin, Germany) for 24 h.
T-cell proliferation
Allogeneic T-cell proliferation was performed using 10 5 lymph node cells obtained from Balb/C mice as responder cells and irradiated (30 Gy) CR1-derived DCs as stimulator cells. On day 3 of culture, the cells were pulsed with 1 mCi 3 H-thymidine for 16 h. Incorporated
Retroviral gene transfer
The MSCV ICN1-IRES-GFP and MSCV IRES GFP retroviral plasmids were kindly provided by Scadden DT, Harvard Medical School, USA. Recombinant VSV-G pseudotyped retroviruses were generated using transient transfection into the packaging cell line 293GPG. 22 For retroviral gene transfer, Sca-1 þ c-kit þ lin À progenitor cells were stimulated for 48 h in the presence of a stem cell cytokine cocktail (10 ng/ml rm-IL-3, 10 ng/ml rm-IL-6, 50 ng/ml rm-SCF, 50 ng/ml rh-Flt3L and 25 ng/ ml h-TPO (all from Peprotech, Rocky Hill, NJ, USA) and transduced at a multiplicity of infection (MOI) of 10 in the presence of 8 mg/ml polybrene (Sigma). The average transduction efficiency was 50-60%.
In vivo studies. Age and sex matched C57BL/6 (H2 b ) mice were purchased from Charles River, Germany. To study in vivo differentiation capacity of CR1 cells, 10 6 CD45.2 þ CR1 cells were intravenously injected into either lethally (9 Gy) or sublethally (4.5 Gy) irradiated CD45.1 þ congenic C57Bl/6 recipient mice. All experimental protocols were approved by the animal protection committee at MHH.
Flow cytometry, immunofluorescence and ELISA
Single-cell suspensions were analyzed by flow cytometry using a FACS-Calibur and CELLQuest software (BD Biosciences, San Jose, CA, USA). The following monoclonal antibodies (all from BD Pharmingen, San Diego, CA , USA, except noted otherwise) were used: CD3e-FITC, CD4-FITC and -PE, CD8a-FITC, -PE and -PerCP, CD11b-FITC and -biotin, CD11c-PE and -APC, CD34-FITC, CD40-FITC and -PE, CD45-PE, CD45.1-biotin, CD45.2-FITC, CD80-FITC and -PE , CD86-FITC and -PE, CD117-PE and -APC, B220-FITC, -PE and -biotin, H2-k b -FITC, I-A b -PE, TER119-biotin, GR-1-FITC and -biotin, IL-7Ra-biotin, FcRg-PE, Sca-1-PE, Flt3-PE, CD45.2-FITC, NK1.1-PE, TLR4-PE and TLR9-FITC (eBiosciences, San Diego, CA, USA). In all experiments, cells were also stained with corresponding isotype-matched monoclonal antibodies. Cells that reacted with biotinylated monoclonal antibodies were incubated with fluorochromeconjugated streptavidin-PerCP or streptavidin-APC (BD Pharmingen). All fluorescence intensity plots are shown in log scales.
For in vitro DC maturation studies, in vitro-differentiated CR1-derived DCs were stimulated in a six-well plate with 10 ng/ml LPS, 100 ng/ml TNF-a (both from Sigma Aldrich) for 24 h.
For cytokine assays, in vitro-differentiated CR1-derived DCs were stimulated in a 96-well plate with 10 ng/ml LPS and 100 ng/ml TNF-a (both from Sigma Aldrich) for 48 h. The supernatants were harvested and IL-12p70 levels were measured using the mouse IL-12p70 ELISA set (BD Pharmingen).
Transwell migration and phagocytosis assays
In vitro migration in response to MIP3b was evaluated using a chemotaxis chamber technique. Cells were washed and plated on the upper compartment of 5-mm pore size transwell plates (Costar, High Wycombe, UK) at 1 Â 10 5 cells/well in 100 ml serum-free IMDM. Then, 100 ng/ml of MIP3b (R&D Systems, Minneapolis, MN, USA) or control serum-free IMDM was added to the lower chamber. After 3 h of incubation at 371C, cells that had transmigrated to the bottom compartment were collected and enumerated. Each experiment was performed in duplicate.
To measure phagocytosis, CR1-derived DCs were incubated in the presence of fluorescein-labelled E. coli for 1 h at either 4 or 371C. After the incubation period, Trypan blue was added to the tubes to quench the fluorescence. Fluorescence was measured by flowcytometry.
RNA extraction and PCR
Total RNA was isolated using commercially available kit systems (Absolutely RNA mini prep kit, Stratagene, La Jolla, CA, USA). cDNA was synthesized using oligo-dT primer and expand reverse transcriptase (Roche). IFN-a mRNA expression was determined by PCR using specific forward primer 5 0 -AGG ACTCATCTGTGGCTTGG and reverse primer 5 0 -ATGCCTGGG GAGAAGATAGG.
Spectratyping and microscopy
For SKY analysis, metaphase chromosomes were hybridized for 3 days with a SKY kit for mouse chromosomes (Applied Spectral Imaging, Migdal HaEmek, Israel). Detection of signals was carried out according to the manufacturer's instructions. We used the SpectraCube system (Applied Spectral Imaging) for image acquisition and the SCYView imaging software (Applied Spectral Imaging) for chromosomal analysis. Phase contrast images of DCs were taken using a Zeiss Axiovert 200 microscope at an original magnification of Â 100. Photodocumentation was performed using an ORCA-2 camera system and Open lab T software.
Statistics
The Kaplan-Meier product-limit method was used to calculate survival rates. Differences between groups were determined using log-rank statistics. P-values p0.05 were considered to be significant.
